Post-Conference Perspectives: Managing R/R B-ALL with CAR T-Cell Therapy - Episode 6

An Oncologist’s Experience With Treating R/R B-ALL With Brexucabtagene Autoleucel in Clinical Practice

Dr Jae Park shares his experience with using brexucabtagene autoleucel for patients with relapsed/refractory B-cell acute lymphoblastic leukemia in clinical practice since its FDA approval in October 2021.

EP. 1: Signs and Symptoms of B-Cell Acute Lymphoblastic Leukemia (B-ALL)
EP. 2: Available Treatment Options for Patients With Relapsed/Refractory (R/R) B-ALL
EP. 3: R/R B-ALL: Key Efficacy Outcomes From the Updated Analysis of the ZUMA-3 Trial
EP. 4: R/R B-ALL: Key Safety Outcomes From the Updated Analysis of the ZUMA-3 Trial
EP. 5: Outcomes Data Following Brexucabtagene Autoleucel Therapy in Patients With R/R B-ALL
Now Viewing
EP. 6: An Oncologist’s Experience With Treating R/R B-ALL With Brexucabtagene Autoleucel in Clinical Practice
EP. 7: The Future of R/R B-ALL Treatment